Tarsus Pharmaceuticals Inc
Research Tarsus Pharmaceuticals Inc (TARS) on Bullrun: market cap USD 3.09B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTARS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.09B
- Financial periodQ2 2026
- RevenueUSD 173.91M
- Net income-USD 18.55M
- Free cash flowUSD 57.15M
- Gross margin93.0%
Valuation Snapshot
latest market cap is USD 3.09B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 451.36M | -USD 66.00M | -USD 22.31M | 93.2% | -1.59 | USD 183.64M | USD 72.44M | USD 343.43M |
| FY2024 | USD 182.95M | -USD 116.00M | -USD 84.59M | 93.0% | -3.07 | USD 94.82M | USD 71.85M | USD 224.53M |
| FY2023 | USD 17.45M | -USD 136.00M | -USD 119.00M | 90.9% | -4.62 | USD 224.95M | USD 29.82M | USD 196.99M |
| FY2022 | USD 25.82M | -USD 62.09M | -USD 49.54M | n/a | -2.52 | USD 71.66M | USD 19.43M | USD 192.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.09B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.48B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.12B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 670.37M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 391.01M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 465.72M | n/a | n/a | n/a |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tarsus Pharmaceuticals Inc's market cap?
Tarsus Pharmaceuticals Inc's market capitalization is USD 3.09B.
What does Tarsus Pharmaceuticals Inc do?
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs.